Skip to main content

Table 2 The changes in study outcomes for all participants at 12 months (N = 111)

From: The impact of antihypertensive treatment initiation on health-related quality of life and cardiovascular risk factor levels: a prospective, interventional study

Outcome At baseline mean (SD) Change at 12 months mean (95% CI) P-value
Office SBP, mmHg 173 (20)  − 22 (− 27 to − 18)  < 0.001
Office DBP, mmHg 102 (12)  − 13 (− 15 to − 10)  < 0.001
Home SBP, mmHg 153 (13)  − 15 (− 18 to − 11)  < 0.001
Home DBP, mmHg 92 (7)  − 10 (− 12 to − 8)  < 0.001
EQ-5D 0.872 (0.153)  − 0.045 (− 0.076 to − 0.015) 0.004
EQ-5D VAS 77 (14) 1 (− 1 to 3) 0.32
Weight, kg 84.1 (17.2) 0.0 (0.7 to 0.7) 0.94
Waist circumference, cm 101 (16)  − 1 (− 3 to 1) 0.21
Total cholesterol, mmol/l 5.36 (1.11)  − 0.37 (− 0.56 to − 0.19)  < 0.001
LDL cholesterol, mmol/l 3.15 (1.01)  − 0.32 (− 0.51 to − 0.13)  < 0.001
HDL cholesterol, mmol/l 1.61 (0.45)  − 0.04 (− 0.08 to 0.01) 0.069
Triglycerides, mmol/l 1.37 (0.98)  − 0.01 (− 0.13 to 0.10) 0.82
Fasting glucose, mmol/l 5.87(0.85)  − 0.07 (− 0.23 to 0.10) 0.40
Alcohol use, AUDIT-C score 3.3 (2.6)  − 0.2 (− 0.5 to − 0.0) 0.048
Physical activity, FIT index 38 (19) 2 (–1 to 5) 0.10
  1. AUDIT-C, alcohol consumption questions from the alcohol use disorders identification test (AUDIT); DBP, diastolic blood pressure, EQ-5D, EuroQoL questionnaire of health-related quality of life; FIT index, Frequency-Intensity-Time (FIT) Index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; VAS, visual analogue scale